Product Description
first C-nucleoside HCV polymerase inhibitor for antiviral response in HCV infected patients (Sourced from: https://pubmed.ncbi.nlm.nih.gov/23547794/)
Mechanisms of Action: HCV-NS5B Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Gilead Sciences
Company Location: Western America
Company CEO: Daniel P. O’Day
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Hepatitis A|Hepatitis C, Chronic
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT01316237 |
GS-US-119-0101 | P1 |
Completed |
Hepatitis C, Chronic|Hepatitis A |
2011-10-01 |
2019-03-19 |
Treatments |